In 2017, the FDA approved two CAR-T cell immunotherapies for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL) targeting CD19 (Chen et al., 2023). Here, CD19 is linked to acute lymphoblastic leukemia.